Form 483

Allergan Pharmaceuticals Ireland Form 483, 2015-07-03

FDA issued a Form 483 to Allergan Pharmaceuticals Ireland on 2015-07-03 with 10 public-safe observations.

483· Form 483 issuedMedical Devices & Rad Health10 observations

Allergan Pharmaceuticals Ireland · Westport, Ireland · Issued July 3, 2015

Overview

  • 10 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

3 Jul 2015
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Margaret M Annes, Philip F Istafanos

3 Jul 2015
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Margaret M Annes, Philip F Istafanos

3 Jul 2015
21 CFR 211.160(b)(4)

Establishment of calibration procedures

Cited by Margaret M Annes, Philip F Istafanos

3 Jul 2015
21 CFR 211.167(a)

Sterility/pyrogens - test methods written, followed

Cited by Margaret M Annes, Philip F Istafanos

3 Jul 2015
21 CFR 314.81(b)(1)(ii)

Failure to meet specifications

Cited by Margaret M Annes, Philip F Istafanos

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations2x
21 CFR 211.160(b)Cited across public-safe Form 483 observations2x
21 CFR 211.160(b)(4)Cited across public-safe Form 483 observations2x
21 CFR 211.167(a)Cited across public-safe Form 483 observations2x
21 CFR 314.81(b)(1)(ii)Cited across public-safe Form 483 observations2x

Full 483 report

Get the verbatim text of all 10 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere